title: Factors associated with publication of randomized phase iii cancer trials in journals with a high impact factor.
abstract: BACKGROUND
  Impact factor (if) is often used as a measure of journal quality. The purpose of the present study was to determine whether trials with positive outcomes are more likely to be published in journals with higher ifs.
  
  
  METHODS
  We reviewed 476 randomized phase iii cancer trials published in 13 journals between 1995 and 2005. Multivariate logistic regression models were used to investigate predictors of publication in journals with high ifs (compared with low and medium ifs).
  
  
  RESULTS
  A positive outcome had the strongest association with publication in high-if journals [odds ratio (or): 4.13; 95% confidence interval (ci): 2.67 to 6.37; p < 0.001]. Other associated factors were a larger sample size (or: 1.06; 95% ci: 1.02 to 1.10; p = 0.001), intention-to-treat analysis (or: 2.53; 95% ci: 1.56 to 4.10; p < 0.001), North American authors (or for European authors: 0.36; 95% ci: 0.23 to 0.58; or for international authors: 0.41; 95% ci: 0.20 to 0.82; p < 0.001), adjuvant therapy trial (or: 2.58; 95% ci: 1.61 to 4.15; p < 0.001), shorter time to publication (or: 0.84; 95% ci: 0.77 to 0.92; p < 0.001), uncommon tumour type (or: 1.39; 95% ci: 0.90 to 2.13; p = 0.012), and hematologic malignancy (or: 3.15; 95% ci: 1.41 to 7.03; p = 0.012).
  
  
  CONCLUSIONS
  Cancer trials with positive outcomes are more likely to be published in journals with high ifs. Readers of medical literature should be aware of this "impact factor bias," and investigators should be encouraged to submit reports of trials of high methodologic quality to journals with high ifs regardless of study outcomes.
authors.affiliation: Department of Medical Oncology, Tom Baker Cancer Centre, Calgary, AB.
authors.forename: P A
authors.initials: PA
authors.lastname: Tang
authors.affiliation: Department of Oncology, Juravinski Hospital and Cancer Centre, Hamilton, ON.
authors.forename: G R
authors.initials: GR
authors.lastname: Pond
authors.affiliation: Department of Medical Oncology, London Regional Cancer Program, London, ON.
authors.forename: S
authors.initials: S
authors.lastname: Welch
authors.affiliation: Department of Medical Oncology and Hematology, Princess Margaret Hospital, and Faculty of Medicine, University of Toronto, Toronto, ON.
authors.forename: E X
authors.initials: EX
authors.lastname: Chen
keywords: Impact factor; cancer trials; predictive factors; publication
references.citation: JAMA. 1998 Jul 15;280(3):246-7
references.pmid: 9676670
references.citation: Cochrane Database Syst Rev. 2009 Jan 21;(1):MR000006
references.pmid: 19160345
references.citation: Am J Gastroenterol. 2005 Nov;100(11):2431-5
references.pmid: 16279896
references.citation: Lancet. 2001 Apr 14;357(9263):1191-4
references.pmid: 11323066
references.citation: Science. 1993 May 14;260(5110):884-6
references.pmid: 8493516
references.citation: Lancet. 2000 Aug 19;356(9230):635-8
references.pmid: 10968436
references.citation: Nature. 2002 Jun 27;417(6892):898
references.pmid: 12087380
references.citation: Nature. 2002 Feb 14;415(6873):726-9
references.pmid: 11845174
references.citation: JAMA. 2002 Jun 5;287(21):2801-4
references.pmid: 12038917
references.citation: Cancer. 2007 Jul 15;110(2):334-9
references.pmid: 17549690
references.citation: JAMA. 1990 Mar 9;263(10):1385-9
references.pmid: 2406472
references.citation: JAMA. 1996 Aug 28;276(8):637-9
references.pmid: 8773637
references.citation: Cochrane Database Syst Rev. 2011 Jan 19;(1):MR000031
references.pmid: 21249714
references.citation: JAMA. 2002 Jun 5;287(21):2825-8
references.pmid: 12038924
references.citation: J Clin Oncol. 2012 Jan 10;30(2):210-6
references.pmid: 22162583
references.citation: Ann Intern Med. 2010 Jun 1;152(11):726-32
references.pmid: 20335313
references.citation: Cancer. 2007 Apr 1;109(7):1239-46
references.pmid: 17326054
references.citation: Cancer. 2005 Oct 1;104(7):1497-504
references.pmid: 16116590
references.citation: Science. 1972 Nov 3;178(4060):471-9
references.pmid: 5079701
references.citation: JAMA. 2003 Jul 23;290(4):495-501
references.pmid: 12876092
references.citation: JAMA. 1999 Sep 15;282(11):1054-60
references.pmid: 10493204
references.citation: Arch Pediatr Adolesc Med. 2005 Nov;159(11):1036-7
references.pmid: 16275793
references.citation: Control Clin Trials. 1996 Feb;17(1):1-12
references.pmid: 8721797
references.citation: JAMA. 2002 Jun 5;287(21):2847-50
references.pmid: 12038930
references.citation: J Clin Oncol. 2008 May 1;26(13):2205-11
references.pmid: 18445846
references.citation: JAMA. 2005 Jul 13;294(2):218-28
references.pmid: 16014596
references.citation: Med J Aust. 2006 Jun 19;184(12):621-6
references.pmid: 16803442
references.citation: BMC Med Res Methodol. 2002 Apr 26;2:7
references.pmid: 11978183
references.citation: BMJ. 2004 Jan 3;328(7430):22-4
references.pmid: 14703540
references.citation: Ann Oncol. 2000 Dec;11(12):1591-5
references.pmid: 11205468
references.citation: BMJ. 1997 Feb 15;314(7079):498-502
references.pmid: 9056804
references.citation: BMJ. 2003 May 31;326(7400):1167-70
references.pmid: 12775614
references.citation: PLoS One. 2008 Aug 28;3(8):e3081
references.pmid: 18769481
references.citation: Ann Oncol. 1992 Mar;3(3):187-91
references.pmid: 1586615
references.citation: J Clin Oncol. 2008 Nov 20;26(33):5458-64
references.pmid: 18955452
references.citation: Lancet. 1991 Apr 13;337(8746):867-72
references.pmid: 1672966